DK2331210T3 - Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika - Google Patents

Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika

Info

Publication number
DK2331210T3
DK2331210T3 DK09778335.1T DK09778335T DK2331210T3 DK 2331210 T3 DK2331210 T3 DK 2331210T3 DK 09778335 T DK09778335 T DK 09778335T DK 2331210 T3 DK2331210 T3 DK 2331210T3
Authority
DK
Denmark
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
DK09778335.1T
Other languages
Danish (da)
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2331210(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK2331210T3 publication Critical patent/DK2331210T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK09778335.1T 2008-09-05 2009-09-04 Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika DK2331210T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
DK2331210T3 true DK2331210T3 (da) 2014-08-11

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09778335.1T DK2331210T3 (da) 2008-09-05 2009-09-04 Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika
DK14000597.6T DK2735338T3 (en) 2008-09-05 2009-09-04 PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PREGABALINE OR GABAPENTIN

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14000597.6T DK2735338T3 (en) 2008-09-05 2009-09-04 PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PREGABALINE OR GABAPENTIN

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2331210B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101851120B1 (enExample)
CN (2) CN105520924B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2331210T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2513394T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20142371A1 (enExample)
PL (2) PL2735338T3 (enExample)
PT (2) PT2735338T (enExample)
RU (2) RU2674150C1 (enExample)
SI (2) SI2735338T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
CA2801620A1 (en) 2010-07-06 2012-01-12 Gruenenthal Gmbh Novel gastro-retentive dosage forms comprising a gaba analog and an opioid
AU2011283462B9 (en) 2010-07-30 2014-09-18 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
DK2680833T3 (en) * 2011-03-04 2016-05-23 Gruenenthal Gmbh PARENTERAL SUBMISSION OF TAPENTADOL
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
WO2013017233A1 (en) * 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9629818B2 (en) * 2012-11-01 2017-04-25 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
KR100758609B1 (ko) 1999-08-20 2007-09-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
JP2005523281A (ja) * 2002-02-22 2005-08-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
PT2012763E (pt) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
KR101607112B1 (ko) * 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
EP2250143B1 (en) * 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물

Also Published As

Publication number Publication date
PT2735338T (pt) 2019-05-24
IL237391A (en) 2017-12-31
JP2017071636A (ja) 2017-04-13
HK1198145A1 (en) 2015-03-13
IL237392A0 (en) 2015-04-30
CN102159284A (zh) 2011-08-17
RU2674150C1 (ru) 2018-12-05
PE20142371A1 (es) 2015-02-04
EP2735338A1 (en) 2014-05-28
PE20190914A1 (es) 2019-06-26
KR20160086981A (ko) 2016-07-20
KR20110057144A (ko) 2011-05-31
AU2018202879B2 (en) 2020-03-12
CA2735857A1 (en) 2010-03-11
AR073361A1 (es) 2010-11-03
SI2331210T1 (sl) 2014-10-30
IL211135A (en) 2017-09-28
AU2016203053B2 (en) 2018-01-25
JP2015096530A (ja) 2015-05-21
KR101641519B1 (ko) 2016-07-21
BRPI0920521A2 (pt) 2018-01-16
HRP20140663T1 (hr) 2014-10-10
HRP20190500T1 (hr) 2019-08-09
ZA201101449B (en) 2011-10-26
PL2735338T3 (pl) 2019-07-31
CA2735857C (en) 2019-05-28
PE20110291A1 (es) 2011-06-04
WO2010025931A2 (en) 2010-03-11
AU2009289776A1 (en) 2010-03-11
RU2571501C2 (ru) 2015-12-20
CY1121492T1 (el) 2020-05-29
EP2735338B1 (en) 2019-02-06
AU2018202879A1 (en) 2018-05-17
CY1115751T1 (el) 2017-01-25
MX2011002339A (es) 2011-04-04
AR117613A2 (es) 2021-08-18
CN105520924B (zh) 2019-04-09
ES2719900T3 (es) 2019-07-16
EP2331210B1 (en) 2014-07-09
SI2735338T1 (sl) 2019-04-30
US20100063148A1 (en) 2010-03-11
ES2513394T3 (es) 2014-10-27
IL237392B (en) 2019-08-29
HUE043278T2 (hu) 2019-08-28
PE20142372A1 (es) 2015-02-04
PT2331210E (pt) 2014-08-25
ECSP11010869A (es) 2011-04-29
TR201904388T4 (tr) 2019-05-21
KR20170048602A (ko) 2017-05-08
AU2016203053A1 (en) 2016-06-02
HK1159011A1 (en) 2012-07-27
JP2012501986A (ja) 2012-01-26
CN105520924A (zh) 2016-04-27
IL211135A0 (en) 2011-04-28
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
CO6382142A2 (es) 2012-02-15
IL237391A0 (en) 2015-04-30
EP2331210A2 (en) 2011-06-15
DK2735338T3 (en) 2019-04-23
PL2331210T3 (pl) 2014-12-31
WO2010025931A3 (en) 2010-06-17
PE20142357A1 (es) 2015-02-04
CN102159284B (zh) 2015-12-09
JP2019131578A (ja) 2019-08-08
JP5731387B2 (ja) 2015-06-10
RU2011112444A (ru) 2012-10-10
KR101730924B1 (ko) 2017-04-27
CL2011000317A1 (es) 2011-06-17

Similar Documents

Publication Publication Date Title
DK2331210T3 (da) Farmaceutisk kombination af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol og et antiepileptika
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
DK3345625T3 (da) Farmaceutisk sammensætning og indgivelser deraf
EP2345410A4 (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BR112012008082A2 (pt) composição farmacêutica e adminstrações da mesma
EP2496691A4 (en) THERAPEUTIC NUCLEASE COMPOSITIONS AND METHOD THEREFOR
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
FI20090502A0 (fi) Hissi, johdekiinnike ja menetelmä
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
BRPI1012246A2 (pt) composição farmacêutica contendo um fármaco e sirna
BRPI0921022A2 (pt) tratamento com pirfenidona para pacientes com função hepática atípica
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
BRPI1015947A2 (pt) dispositivos para distribuição de fármacos e sistemas e métodos relacionados
DK2437830T3 (da) Anordning til lægemiddelleveringsindretning og lægemiddelleveringsindretning
BRPI1015124A2 (pt) compostos aromáticos substituídos e usos farmacêuticos dos mesmos
BRPI0807907A2 (pt) co-cristais e composições farmacêuticas compreendendo os mesmos.
BRPI1011726A2 (pt) combinação de eixo e mancal e dispositivo de administraçãos de fármaco
BRPI0811919A2 (pt) Medicamento para tratamento do mal de alzheimer
DK2086213T3 (da) Billedlæseapparat og billeddannelseapparat
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
BRPI0914180A2 (pt) composição à base de flavanolignano e método para preparação da mesma